FibroGen, Inc (NASDAQ:FGEN) insider K Peony Yu sold 2,851 shares of the company’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $51.00, for a total transaction of $145,401.00. Following the sale, the insider now directly owns 185,546 shares of the company’s stock, valued at approximately $9,462,846. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

K Peony Yu also recently made the following trade(s):

  • On Monday, August 21st, K Peony Yu sold 7,500 shares of FibroGen stock. The shares were sold at an average price of $41.03, for a total transaction of $307,725.00.
  • On Tuesday, August 8th, K Peony Yu sold 37,500 shares of FibroGen stock. The shares were sold at an average price of $50.58, for a total transaction of $1,896,750.00.
  • On Tuesday, August 1st, K Peony Yu sold 10,000 shares of FibroGen stock. The shares were sold at an average price of $33.48, for a total transaction of $334,800.00.
  • On Monday, July 10th, K Peony Yu sold 5,000 shares of FibroGen stock. The shares were sold at an average price of $32.98, for a total transaction of $164,900.00.

Shares of FibroGen, Inc (FGEN) traded up 0.58% on Friday, hitting $52.40. The company had a trading volume of 1,462,946 shares. FibroGen, Inc has a 52 week low of $15.60 and a 52 week high of $52.70. The stock’s 50-day moving average is $43.31 and its 200 day moving average is $32.07. The company’s market capitalization is $3.73 billion.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. Equities analysts expect that FibroGen, Inc will post ($1.80) EPS for the current year.

TRADEMARK VIOLATION WARNING: “FibroGen, Inc (FGEN) Insider K Peony Yu Sells 2,851 Shares of Stock” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/09/16/fibrogen-inc-fgen-insider-k-peony-yu-sells-2851-shares-of-stock.html.

Several equities research analysts have recently commented on FGEN shares. Stifel Nicolaus reaffirmed a “buy” rating and set a $38.00 price target (up previously from $32.00) on shares of FibroGen in a research report on Thursday, June 22nd. BidaskClub raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. William Blair reiterated an “outperform” rating on shares of FibroGen in a research note on Monday, June 26th. Citigroup Inc. reiterated a “buy” rating and set a $48.00 price objective on shares of FibroGen in a research note on Monday, June 26th. Finally, Jefferies Group LLC began coverage on FibroGen in a research note on Monday, July 10th. They set a “buy” rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. FibroGen has an average rating of “Buy” and an average price target of $60.17.

Hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. purchased a new position in FibroGen during the first quarter valued at approximately $111,000. Quantbot Technologies LP purchased a new position in FibroGen during the second quarter valued at approximately $128,000. SG Americas Securities LLC raised its position in FibroGen by 6.5% during the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 412 shares in the last quarter. Airain ltd purchased a new position in FibroGen during the first quarter valued at approximately $236,000. Finally, Amalgamated Bank purchased a new position in FibroGen during the second quarter valued at approximately $237,000. Institutional investors own 47.49% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.